natgillin/translations-raw huggingface dataset:
The CVMP concluded that the benefits of Flexicam exceed the risks for the alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders, reduction of post- operative pain and inflammation following orthopaedic and soft tissue surgery in dogs and reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats and recommended that Flexicam be given a marketing authorisation.
koristi zdravila Flexicam pri umirjanju vnetja in lajšanju bolečine pri akutnih in kroničnih mišično- skeletnih obolenjih, lajšanju pooperativne bolečine in vnetja po ortopedskih operacijah in operacijah mehkega tkiva pri psih ter lajšanju pooperativne bolečine po ovariohisterektomiji in manjših operacijah mehkega tkiva pri mačkah večje od z njim povezanih tveganj, in priporočil, da se za zdravilo Flexicam odobri dovoljenje za promet.
The CVMP concluded that the benefits of Nexgard Spectra exceed the risks for the approved indications and recommended that Nexgard Spectra be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Nexgard Spectra večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The CVMP concluded that the benefits of ProZinc exceed the risks for the approved indication and recommended that ProZinc be given a marketing authorisation.
CVMP je zaključil, da so koristi zdravila ProZinc večje od z njim povezanih tveganj v okviru odobrene indikacije, in priporočil, da se zanj odobri dovoljenje za promet.
The CVMP considered that the medicine was effective in eliminating flea infestations and controling and preventing new flea and tick infestations for up to three to four weeks after treatment.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je menil, da je zdravilo učinkovito pri zdravljenju infestacij z bolhami ter nadzoru in preprečevanju novih infestacij z bolhami in klopi do tri ali štiri tedne po zdravljenju.
The CVMP considered that, in accordance with European Union requirements, Loxicom has been shown to be bioequivalent to Metacam.
CVMP meni, da je zdravilo Loxicom v skladu z zahtevami Evropske unije biološko enakovredno zdravilu Metacam.
The CVMP considered that, in accordance with European Union requirements, Rheumocam has been shown to be bioequivalent to Metacam.
CVMP je menil, da je bilo dokazano, da je zdravilo Rheumocam v skladu z zahtevami Evropske unije biološko enakovredno zdravilu Metacam.
The CVMP therefore concluded that the benefits of Activyl Tick Plus exceed the risks and recommended that it be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zato zaključil, da so koristi zdravila Activyl Tick Plus večje od z njim povezanih tveganj.
The cyclooxygenase enzyme (COX) is present in two forms.
Encim ciklooksigenaza se nahaja v dveh oblikah.
The cylinders may be discarded with the bottle after use.
Po uporabi lahko valjčka odvržete skupaj s plastenko.
The CYP2C19 inhibitor omeprazole (40 mg q.d.) did not give rise to a clinically significant change in lacosamide exposure.
Omeprazol, zaviralec CYP2C19, (40 mg na dan) ni povečal klinično pomembnih sprememb v izpostavljenosti lakozamida.
The CYP2C19*2 and CYP2C19*3 alleles account for the majority of reduced function alleles in Caucasian (85%) and Asian (99%) poor metabolisers.
Na račun alelov CYP2C19*2 in CYP2C19*3 gre večina alelov z zmanjšanim delovanjem pri Kavkazijcih(85 %) in pri Azijcih (99 %), ki so slabi metabolizatorji.
The cytotoxic actions of porfimer sodium are light and oxygen-dependent.
Citotoksični učinki PhotoBarra so blagi in odvisni od kisika.
The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position.
Citotoksičnost MTIK je verjetno predvsem posledica alkiliranja gvanina na položaju O6, z dodatnim alkiliranjem na položaju N7.
The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position.
Menijo, da je glavni vzrok citotoksičnosti MTIC alkilacija na položaju gvanina O6 z dodatno alkilacijo, ki se tudi zgodi na položaju N7.
The cytotoxicity of MTIC is thought to be dueprimarily to alkylation at the O6 position of guanine with additional alkylation also occurring at the N7 position.
Menijo, da je glavni vzrok citotoksičnosti MTIC alkilacija na položaju gvanina O6 z dodatno alkilacijo, ki se tudi zgodi na položaju N7.
The dabigatran AUC and Cmax were increased by about 60 % and 50 %, respectively.
AUC dabigatrana se je povečala za približno 60 % Cmax pa za približno 50 %.
The dabigatran geometric mean trough concentration, measured at trough in the morning, at the end of the dosing interval (i.e.
12 ur po odmerku 150 mg zvečer), je bila v povprečju 91.0 ng/ml, njen razpon pa je bil 61.0-143 ng/ml (25. do 75. percentile).
The dabigatran geometric mean trough concentration, measured at trough in the morning, at the end of the dosing interval (i.e.
Geometrična sredina najmanjše koncentracije dabigatrana, merjena zjutraj na koncu odmernega intervala (t.j.
The dabigatran trough concentrations were about 20 % lower in patients with a body weight > 100 kg compared with 50-100 kg.
Najmanjše koncentracije dabigatrana so dosegli bolniki s telesno maso nad 100 kg, in sicer za približno 20 % manjše kot pri bolnikih s telesno maso 50 do 100 kg.
The dabrafenib capsules are to be swallowed whole with water.
Kapsule z dabrafenibom je treba zaužiti cele z vodo.
The dabrafenib monotherapy safety profile is based on data from five clinical studies and included 578 patients with melanoma.
Varnostni profil dabrafeniba v monoterapiji temelji na podatkih petih kliničnih študij, ki so zajele 578 bolnikov z melanomom.
The daily amount of asparaginase needed per patient can be diluted in a final volume of 50 – 250 ml sodium chloride 9 mg/ml (0.9 %) solution for injection.
Dnevno količino asparaginaze, ki jo bolnik potrebuje, lahko razredčite v končnem volumnu 50-250 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje.
The daily amount of Spectrila needed per patient can be diluted in a final volume of 50 - 250 ml sodium chloride 9 mg/ml (0.9 %) solution for injection.
Dnevno količino zdravila Spectrila, ki jo bolnik potrebuje, lahko razredčite v končnem volumnu 50-250 ml raztopine natrijevega klorida 9 mg/ml (0,9 %) za injiciranje.
The daily cataplexy rate (geometric means) was 0.52 at baseline and 0.18 at final visit for pitolisant and 0.43 at baseline and 0.39 at final visit for placebo, with a rate ration rR=0.38 [0.16 ; 0.93] (p=0.034).
Delež dnevne katapleksije (geometrijska sredina) je bil pri pitolizantu 0,52 ob izhodišču in 0,18 ob zadnjem obisku, pri placebu pa 0,43 ob izhodišču in 0,39 ob zadnjem obisku, z razmerjem incidence rR = 0,38 (0,16; 0,93) (p = 0,034).
The daily dosage is administered in equally divided doses 3 times a day.
Dnevni odmerek damo razdeljen v tri enake odmerke.
The daily dosage of clobazam and/or valproate should be reduced according to the onset of side effects whilst on stiripentol therapy (see section 4.2).
Dnevno odmerjanje klobazama ali valproata ali obojega je treba znižati, če se pojavijo neželeni učinki med zdravljenjem z Diacomit. (glejte poglavje 4.2).
The daily dose depends on the child’s body surface area, and infusions are given over 10 hours.
Dnevni odmerek je odvisen od otrokove telesne površine, infundiranje pa traja 10 ur.
The daily dose depends on the patient’s body weight.
Dnevni odmerek je odvisen od telesne mase bolnika.
The daily dose is 10 mL suspension (2 g of the medicine) taken as 2 separate doses.
Dnevni odmerek je 10 ml suspenzije (2 g zdravila), razdeljenih na dva posamezna odmerka.
The daily dose is 12 capsules (3 g of the medicine) taken as 2 separate doses.
Dnevni odmerek je 12 kapsul (3 g zdravila), razdeljenih na 2 posamezna odmerka.
The daily dose is 12 capsules (3 g of the medicine) taken as 2 separate doses.
Dnevni odmerek so 12 kapsul (3 g zdravila), ki se jemljejo v 2 posameznih odmerkih.
The daily dose is 15 mL suspension (3 g of the medicine) taken as 2 separate doses.
Dnevni odmerek je 15 ml suspenzije (3 g zdravila), razdeljenih na dva posamezna odmerka.
The daily dose is 2 g of the medicine taken as 2 separate doses.
Dnevni odmerek je 2 g zdravila, razdeljena na 2 posamezna odmerka.
The daily dose is 4 tablets (2 g of the medicine) taken as 2 separate doses.
Dnevni odmerek je 4 tablete (2 g zdravila), razdeljenih na 2 posamezna odmerka.
The daily dose is 4 tablets (2 g of the medicine) taken as 2 separate doses.
Dnevni odmerek so 4 tablete (2 g zdravila), ki se jemlje v 2 posameznih odmerkih.
The daily dose is 6 tablets (3 g of the medicine) taken as 2 separate doses.
Dnevni odmerek je 6 tablet (3 g zdravila), razdeljenih na 2 posamezna odmerka.
The daily dose is 6 tablets (3 g of the medicine) taken as 2 separate doses.
Dnevni odmerek so 6 tablet (3 g zdravila), ki se jemljejo v 2 posameznih odmerkih.
The daily dose is 8 capsules (2 g of the medicine) taken as 2 separate doses.
Dnevni odmerek je 8 kapsul (2 g zdravila), razdeljenih na 2 posamezna odmerka.
The daily dose is 8 capsules (2 g of the medicine) taken as 2 separate doses.
Dnevni odmerek so 8 kapsul (2 g zdravila), ki se jemlje v 2 posameznih odmerkih.
The daily dose is between 5 and 15 mg per kg body weight, adjusted for each patient according to the state of their bile acid, with a minimum daily dose of 50 mg and a maximum of
Dnevni odmerek je med 5 in 15 mg na kg telesne mase, ki se pri posameznem bolniku
The daily dose is chosen and adjusted during treatment for each patient depending on the patient’s levels of bile acids in their blood and urine and their liver function.
Dnevni odmerek se določi in nato prilagaja med zdravljenjem za vsakega bolnika posebej glede na ravni žolčnih kislin v krvi in urinu ter delovanje jeter.
The daily dose is to be taken divided into 3 equal doses.
Dnevni odmerek je treba razdeliti in ga vzeti v 3 enakih odmerkih.
The daily dose may be divided if it consists of more than one capsule in order to mimic the continuous production of cholic acid in the body, and to reduce the number of capsules that need to be taken per administration.
Dnevni odmerek se lahko razdeli, če je sestavljen iz več kapsul, da se posnema stalno nastajanje holne kisline v telesu in da se zmanjša število kapsul, ki jih je treba vzeti pri vsakem odmerjanju.
The daily dose may be lowered if needed to reduce side effects.
Dnevni odmerek se lahko zniža, če je treba zmanjšati neželene učinke.
The daily dose must be individualised according to renal function.
Dnevni odmerek je potrebno prilagoditi individualno glede na delovanje ledvic.
The daily dose of Ammonaps is adjusted for each patient individually and depends on the patient’s diet, height and weight.
Dnevni odmerek zdravila Ammonaps je prilagojen za vsakega bolnika posebej in je odvisen od bolnikove prehrane, višine in telesne mase.
the daily dose of ketoconazole should not exceed 200 mg.
odmerek ketokonazola ne sme
The daily dose of levodopa should be reduced by about 10-30% by extending the dosing intervals and/or by reducing the amount of levodopa per dose, according to the clinical condition of the patient.
Glede na bolnikovo klinično stanje je treba dnevni odmerek levodope zmanjšati za približno 10– 30 %, in sicer s podaljšanjem časovnega presledka med posameznimi odmerki in/ali z zmanjšanjem količine levodope na odmerek.
The daily dose of levodopa should be reduced by about 10–30% by extending the dosing intervals and/or by reducing the amount of levodopa per dose, according to the clinical condition of the patient.
Glede na bolnikovo klinično stanje je treba dnevni odmerek levodope zmanjšati za približno 10-30 %, in sicer s podaljšanjem časovnega presledka med posameznimi odmerki in/ali z zmanjšanjem količine levodope na odmerek.
The daily dose of olanzapine is between 5 mg and 20 mg.
Dnevni odmerek zdravila OLANZAPIN MYLAN je med 5 mg in 20 mg.
The daily dose of Olazax Disperzi is between 5 mg and 20 mg.
Dnevni odmerek zdravila Olazax Disperzi je med 5 mg in 20 mg.
The daily dose of Pheburane is adjusted for each patient individually and depends on the patient’s diet, height and weight.
Dnevni odmerek zdravila Pheburane je prilagojen za vsakega bolnika posebej in je odvisen od bolnikove prehrane, višine in telesne mase.
The daily dose of PHEBURANE will be based on your body weight or body surface and adjusted according to your protein tolerance and diet.
Dnevni odmerek zdravila PHEBURANE vam bodo določili na podlagi vaše telesne mase ali telesne površine in bo prilagojen glede na vašo toleranco za beljakovine in glede na vašo prehrano.
The daily dose of Ravicti depends on the patient’s diet, height and weight.
Dnevni odmerek zdravila Ravicti je odvisen od bolnikove prehrane, telesne višine in mase.
The daily dose of Revolade should not exceed 100 mg.
Dnevni odmerek zdravila Revolade ne sme preseči 100 mg.
The daily dose should be individually adjusted according to the patient’s estimated urea synthetic capacity, if any, amino acid profile, protein tolerance and the daily dietary protein intake needed to promote growth and development.
Dnevni odmerek je treba individualno prilagajati glede na bolnikovo ocenjeno sposobnost sinteze sečnine, če do sinteze sečnine sploh prihaja, tolerance na beljakovine in dnevni vnos prehranskih beljakovin, ki so potrebne za pospeševanje rasti in razvoja.
The daily dose should be individually adjusted according to the patient’s protein tolerance and the daily dietary protein intake needed to promote growth and development.
Dnevni odmerek je treba prilagoditi individualno glede na bolnikovo toleranco za beljakovine in na potreben dnevni vnos beljakovin za pospeševanje rasti in razvoja.
The daily dose should be individually adjusted according to the patient’s protein tolerance and the daily dietary protein intake needed to promote growth and development.
Dnevni odmerek se mora prilagoditi individualno glede na bolnikovo toleranco za beljakovine in na potreben dnevni vnos beljakovin za pospeševanje rasti in razvoja.
The daily dose should be individually adjusted according to the patient’s protein tolerance and the daily dietary protein intake needed.
Dnevni odmerek je treba individualno prilagajati glede na bolnikovo toleranco na beljakovine in potrebni dnevni vnos prehranskih beljakovin.
The daily dose should be reduced by half in patients with moderate or severely reduced kidney function.
Pri bolnikih z zmerno ali močno oslabljenim delovanjem ledvic je treba dnevni odmerek zmanjšati za polovico.
The daily dose should be reduced in steps of 1 mg/24 h with a dose reduction preferably every other day, until complete withdrawal of Leganto (see section 4.4).
Dnevni odmerek je treba zmanjševati po 1 mg/24 h, po možnosti vsak drugi dan, do popolne odtegnitve zdravila Leganto (glejte poglavje 4.4).
The daily dose should be reduced in steps of 1 mg/24 h with a dose reduction preferably every other day, until complete withdrawal of Neupro (see section 4.4).
Dnevni odmerek je treba zmanjševati po 1 mg/24 h, po možnosti vsak drugi dan, do popolne odtegnitve zdravila Neupro (glejte poglavje 4.4).
The daily dose should not exceed 75 mg in ITP patients and 150 mg in severe aplastic anaemia patients.
Dnevni odmerek ne sme biti višji od 75 mg pri bolnikih z imunsko trombocitopenično purpuro in 150 mg pri tistih s hudo aplastično anemijo.
The daily dose was escalated to 800 mg in a total of 103 patients; 6 patients achieved a partial response and 21 stabilisation of their disease after dose escalation for an overall clinical benefit of 26%.
Odmerek so zvečali na 800 mg na dan pri vsega skupaj 103 bolnikih; po zvečanju odmerka je 6 bolnikov doseglo delni odziv, 21 pa stabilizacijo svoje bolezni, kar je pomenilo celotno klinično koristnost 26 %.
The daily injection
Dnevna injekcija
The daily insulin requirement may be higher in patients with insulin resistance (e.g. during puberty or due to obesity) and lower in patients with residual, endogenous insulin production.
Dnevna potreba po insulinu je lahko vecja pri bolnikih z odpornostjo proti insulinu (npr. med puberteto pri mladih ali zaradi debelosti) in manjša pri bolnikih z rezidualnim endogenim nastajanjem insulina.
The daily intake of fat should be distributed over three main meals.
Skupno dnevno količino maščob mora bolnik porazdeliti med tri glavne obroke.
The daily maintenance dose is between 200 mg and 400 mg.
Dnevni vzdrževalni odmerek je med 200 mg in 400 mg.
The daily maintenance dose seldom exceeds 1.0 mg per day.
Dnevni vzdrževalni odmerek redko preseže 1,0 mg na dan.
The dalbavancin plasma concentration-time following the two-dose and the single-dose regimens, respectively, are shown in Figure 1.
Odvisnot koncentracije dalbavancina v plazmi od časa po uporabi režima z enkratnim odmerkom oziroma dvema odmerkoma, kot je prikazano na sliki 1.
The darbepoetin alfa in Aranesp is produced by a method known as ‘recombinant DNA technology’: it is made by cells into which a gene (DNA) has been introduced, which make the cells able to produce darbepoetin alfa.
Darbepoetin alfa proizvajajo z metodo, znano kot „tehnologija rekombinantne DNK“, pri kateri se v celice vstavi gen (DNK), ki jim omogoča tvorjenje darbepoetina alfa.
The dark blue cap is imprinted with Raptor logo in white ink and the light blue body is imprinted with “75 mg” in white ink.
Na temnomodrem pokrovčku je z belim črnilom odtisnjen logotip družbe Raptor, na svetlomodrem osrednjem delu pa je odtisnjena bela oznaka „75 mg‟.
The dark purple colour of the solution, together with the amber vials makes a visual check for particulates impossible.
Zaradi temno vijolične barve raztopine in rumenkasto rjave barve vial ni mogoče videti, ali raztopina vsebuje delce.
The dasabuvir exposures obtained with the 400 mg formulation and the 250 mg tablet are similar.
Izpostavljenosti dasabuvirju, ki so bile dosežene pri 400 mg formulaciji in 250 mg tableti so podobne.
The data are limited but suggest that the pharmacokinetic profile in children and adolescents may be similar to that in adults.
Podatkov je malo, vendar nakazujejo, da utegne biti farmakokineticni profil pri otrocih in mladostnikih podoben kot pri odraslih.
The data available (see section 5.3) warrant caution in patients at risk of QT prolongation (long congenital QT, hypokalaemia).
Razpoložljivi podatki (glejte poglavje 5.3) zahtevajo previdnost pri bolnikih s tveganjem za podaljšanje QT intervala (prirojeni daljši QT interval, hipokaliemija).
The data available from a rat embrofetal development study, where animals were given sodium aminosalicylate (3.85 to 385 mg/kg) were limited.
Podatki, ki so bili na voljo iz študije embriofetalnega razvoja, opravljene na podganah, ki so jim dajali natrijev aminosalicilat (od 3,85 do 385 mg/kg), so bili omejeni.
The data collected suggests that Parkinson’s disease, and not any medicinal products in particular, is associated with a higher risk of skin cancer (not exclusively melanoma).
Zbrani podatki nakazujejo, da je Parkinsonova bolezen, ne pa zdravila sama po sebi, povezana z visokim tveganjem karcinoma kože (ne izključno melanoma).
The data collected suggests that Parkinson’s disease, and not any medicinal products in particular, is associated with a higher risk of skin cancer (not exclusively melanoma).
Zbrani podatki nakazujejo, da je Parkinsonova bolezen, ne pa zdravila sama po sebi, povezana z višjim tveganjem karcinoma kože (ne izključno melanoma).
The data described below reflect exposure of 162 Cushing’s disease patients to Signifor in the phase III study.
Spodaj prikazani podatki odražajo izpostavljenost zdravilu Signifor pri 162 bolnikih s Cushingovo boleznijo v študiji faze III.
The data described below reflect exposure to Benlysta 10 mg/kg in 674 patients with SLE, including 472 exposed for at least 52 weeks.
Spodaj opisani podatki se nanašajo na izpostavljenost zdravilu Benlysta v odmerku 10 mg/kg pri 674 bolnikih s SLE, vključno s 472 bolniki, ki so mu bili izpostavljeni vsaj 52 tednov.
The data described below reflect exposure to SPRYCEL in 2,712 patients in clinical studies, including 324 patients with newly diagnosed chronic phase CML and 2,388 patients with imatinib resistant or intolerant CML or Ph+ ALL.
Podatki, navedeni v nadaljevanju, so bili pridobljeni pri 2.712 bolnikih, ki so v kliničnih študijah prejemali zdravilo SPRYCEL, in vključujejo 324 bolnikov z na novo diagnosticirano KML v kroničnem obdobju ter 2.388 bolnikov s KML ali Ph+ ALL, ki se na predhodno zdravljenje z imatinibom niso odzvali ali ga niso prenašali.
The data described below reflect exposure to Tasigna in 279 patients from a randomised Phase III study in patients with newly diagnosed Ph+ CML in chronic phase treated with 300 mg of nilotinib twice daily.
Spodaj opisani podatki se nanašajo na 279 bolnikov, ki so bili izpostavljeni zdravilu Tasigna, in sicer v randomizirani študiji faze III pri bolnikih z novo odkrito KML s prisotnim kromosomom Philadelphia v kronični fazi, v kateri so prejemali odmerek 300 mg nilotiniba dvakrat dnevno.
The data described below reflect exposure to Tasigna in a total of 717 patients from a randomised Phase III study in patients with newly diagnosed Ph+ CML in chronic phase treated at the recommended dose of 300 mg twice daily (n=279) and from an open-label multicentre Phase II study in patients with imatinib-resistant or intolerant CML in chronic phase (n=321) and accelerated phase (n=137) treated at the recommended dose of 400 mg twice daily.
Spodaj opisani podatki se nanašajo na skupno 717 bolnikov, ki so bili izpostavljeni zdravilu Tasigna, in sicer v randomizirani študiji faze III pri bolnikih z novo odkrito KML s prisotnim kromosomom Philadelphia v kronični fazi, v kateri so prejemali priporočeni odmerek 300 mg dvakrat dnevno (n=279), in v odprti multicentrični študiji faze II pri bolnikih z rezistenco na imantinib ali neprenašanjem imatiniba in s kronično (n=321) ali s pospešeno fazo KML (n=137), v kateri so prejemali priporočeni odmerek 400 mg dvakrat dnevno.
The data described below reflect exposure to Zyclara or vehicle in 319 subjects enrolled in two double-blind studies.
Spodaj prikazani podatki odražajo izpostavljenost zdravilu Zyclara ali vehiklom (nosilcem kreme) pri 319 bolnikih, vključenih v dve dvojno slepi študiji.
The data do not suggest a correlation between the presence of NAb and LDL-C lowering efficacy or safety.
Ti podatki ne kažejo, da bi obstajala korelacija med prisotnostjo NPt in učinkovitostjo znižanja LDL-H ali varnostjo.
The data from the published studies showed that Busilvex in combination with fludarabine was effective as a ‘reduced-intensity’ conditioning treatment, with complete engraftment achieved in 80 to 100% of patients.
Podatki iz objavljenih študij so pokazali, da je bilo zdravilo Busilvex v kombinaciji s fludarabinom učinkovito kot pripravljalno zdravljenje z zmanjšano jakostjo, saj je bilo popolno prijetje doseženo pri 80 do 100 % bolnikov.
The data from this study indicate that bosutinib does not prolong the QT interval in healthy subjects at the recommended dose of 500 mg daily with food, and under conditions that give rise to supratherapeutic plasma concentrations.
Podatki iz študije kažejo, da bosutinib pri zdravih preiskovancih, ki so prejemali priporočeni odmerek 500 mg na dan skupaj s hrano, in v okoliščinah, ki povzročijo supraterapevtske plazemske koncentracije, ne podaljša intervala QT.
The data in Table 1 below describe adverse reactions reported from Phase II and III clinical trials in patients with osteoporosis and breast or prostate cancer patients receiving hormone ablation; and/or spontaneous reporting.
Podatki v spodnji tabeli 1 navajajo neželene učinke, poročane v kliničnih preskušanjih II. in III. faze pri bolnicah oz. bolnikih z osteoporozo ter bolnicah z rakom dojke ali bolnikih z rakom prostate, deležnih ablacije hormonov, in/ali poročane spontano.